Navigation Links
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Date:5/20/2009

duct candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.

    Contact Information

    US Media:                             European Media:
    Andrea tenBroek/Chris Stamm           Ludger Wess
    (781)-684-0770                  
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... 02, 2015 , ... Sleepless nights will become obsolete as Luzi , ... Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will love ... use, while the integration of the Bluetooth speaker, alarm clock and ability to charge ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
(Date:7/1/2015)... AURORA, Colo. and BANGALORE, India ... a global genomic profiling company that uses next generation ... appointment of Scott A. Storrer as chief ... and CEO, he will be responsible for all strategy, ... Vijay Chandru , who has served as Strand,s chairman ...
(Date:7/1/2015)... July 1, 2015 Isagenix International, a leading ... three Gold, three Silver, and three Bronze Stevie® Awards ... in Chicago this month.The ... business awards program in the U.S. ... strength in developing leaders, cultivating talent, creating a unified ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... IDIX ) announced today that Idenix management will ... Health Care Conference on Monday, May 18, 2009 at 8:40 ... webcast of the company presentation can be accessed under "Calendar ... www.idenix.com . Please log in approximately 5-10 minutes ...
... Trait Will Benefit Everyone from Farmers to Consumers. , ... Wilmington, DE ... reached a regulatory milestone for its next generation of healthier soybean products. ... Canada and the Canadian Food Inspection Agency that its ...
... WHAT: GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, ... company developing human, ... Virus) and other infectious agents to share their strategy for, ... plans to expand preventative trials, currently in, ...
Cached Biology Technology:DuPont Receives Canadian Regulatory Approval for High Oleic Soybean Trait 2DuPont Receives Canadian Regulatory Approval for High Oleic Soybean Trait 3
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... Virology of the GSF National Research Center for ... Research Centres) the group is continuing to search for ... of a prion infection. In collaboration with colleagues from ... Heidelberg, the group used micro-array technologies micro-arrays ...
... plant cell biologist at UC Riverside has received a ... investigate how plant stem-cells maintain their identity and how ... According to G. Venugopala Reddy, the principal investigator of ... on plants, has potential to lead to better insights ...
... infant formula-- may reduce a babys susceptibility to rotavirus ... a University of Illinois study published in Septembers Journal ... diarrhea in infants, affecting virtually all children before age ... dehydration, doctors visits, and parents missing work to care ...
Cached Biology News:Prions and retroviruses -- an unholy alliance? 2UCR plant cell biologist to study how plant stem cells maintain and change their identity 2Soy isoflavone may inhibit common gastrointestinal illness in infants 2
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: